{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092270","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.651209+00:00","generated_at":"2026-05-31T11:51:58.465152+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tango Therapeutics Q2 2024 net loss $25.6M; cash $322M, runway to 2027","bullets":["Net loss $25.6M ($0.24/share) vs $20.7M loss ($0.23/share) in Q2 2023.","Collaboration revenue $7.8M, down from $9.6M YoY; license revenue $12.1M (incl. $12M Gilead fee).","R&D expenses $38.7M, up from $28.7M YoY due to clinical program advancement.","Cash, equivalents and marketable securities $322.1M; expected to fund operations into 2027.","PRMT5 program (TNG908/TNG462) dose expansion ongoing; comprehensive data update expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092270","json":"https://secwatch.observer/filing/0000950170-24-092270.json","markdown":"https://secwatch.observer/filing/0000950170-24-092270.md","text":"https://secwatch.observer/filing/0000950170-24-092270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024092270/0000950170-24-092270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024092270/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:51:58.465152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}